Interview: Diane Gosselin, President and CEO, CQDM, Canada
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
CQDM is a not-for-profit organization whose mission is to identify, fund and support joint research projects between the academic and private biopharmaceutical sectors. Projects funded by CQDM target the development of innovative tools and technologies that accelerate the drug discovery process.
Objectives
CQDM is dedicated first and last to the stimulation of research in the field of therapeutic medicine and in particular to the development of innovative tools facilitating the discovery of safer and more effective compounds. By promoting synergy between academic and industrial research and by creating an international exchange network, CQDM intends to expand Quebec’s leadership in biopharmaceutical research and open new research avenues that will have a strong impact on the industry. CQDM activities also benefit small biotechnology companies. Its unique team approach favours access to internationally renowned experts. By leading research efforts towards market expectations, CQDM fully plays its role in disseminating knowledge and creating economic value.
Québec Consortium for Drug Discovery (CQDM)
7140, Albert-Einstein, suite 100
Montreal (Québec) Canada
H4S 2C1
Tel.: 514 766-6661
Fax: 514 766-9613
email: cqdm@cqdm.org
http://www.cqdm.org/en/index.php
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising…
See our Cookie Privacy Policy Here